Form 8-K - Current report

0001676725false00016767252023-11-142023-11-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2023

IDEAYA Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38915		47-4268251
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

7000 Shoreline Court, Suite 350

South San Francisco, California 94080
(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: [phone]

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		IDYA		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

---

Item 1.01 Entry into a Material Definitive Agreement.

On November 14, 2023, IDEAYA Biosciences, Inc. (the “Company”) entered into an Office Lease Agreement (the “Lease”), dated November 14, 2023, with AAT TORREY 13-14, LLC (“Landlord”). Pursuant to the Lease, the Company will lease approximately 6,000 square feet of office space at 11710 El Camino Real, San Diego, in replacement of and expansion to the Company’s current office space in San Diego. The Lease will have an initial term of four (4) years and three (3) months from the later of the date that Landlord substantially completes certain pre-occupancy work or December 1, 2023, and in any event no later than January 1, 2024. Pursuant to the Lease, the Company has one (1), 3-year option to renew the lease at the then-prevailing market rental rate. The Lease provides for total base rent over the initial term, net of rent abatement, of one million five hundred eighty-one thousand four hundred sixty-nine dollars in U.S. dollars ($1,581,469 USD). The Lease contains customary provisions allowing Landlord to terminate the Lease if the Company fails to remedy a breach of any of its obligations within specified time periods. The Company and Landlord have made customary representations, warranties and covenants in the Lease.

The foregoing is only a summary description of the terms of the Lease, does not purpose to be complete and is qualified in its entirety by reference to the Lease, which will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2023.

 

 

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IDEAYA BIOSCIENCES, INC.
Date: November 17, 2023	By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer

 

 

|||

---

Document and Entity Information	Nov. 14, 2023
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001676725
Document Type	8-K
Document Period End Date	Nov. 14, 2023
Entity Registrant Name	IDEAYA Biosciences, Inc.
Entity Incorporation, State or Country Code	DE
Securities Act File Number	001-38915
Entity Tax Identification Number	47-4268251
Entity Address, Address Line One	7000 Shoreline Court
Entity Address, Address Line Two	Suite 350
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	(650)
Local Phone Number	443-6209
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	IDYA
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	true

---